미국의 의약품 시장 : 시장 규모, 점유율 및 동향 분석 보고서 - 분자별, 제품 유형별, 투여 경로별, 질환별, 연령층별, 유통 채널별, 부문별 예측(2025-2030년)

U.S. Pharmaceutical Market Size & Trends:

The U.S. pharmaceutical market size was estimated at USD 634.32 billion in 2024 and is expected to grow at a CAGR of 5.72% from 2025 to 2030, to reach an estimated value of USD 883.97 billion by 2030. This growth can be attributed to the rising prevalence of chronic diseases, increasing geriatric population, growing healthcare expenditure by government organizations, and extensive efforts to improve the affordability & accessibility of pharmaceuticals.

The U.S. pharmaceutical industry has experienced significant growth due to advancements in therapeutics and a robust product pipeline. The development of targeted therapies, biologics, and personalized medicine has reshaped treatment model, offering more effective solutions for complex conditions such as cancer, autoimmune diseases, and genetic disorders. Gene therapies and RNA-based treatments, like those for inherited retinal diseases and certain types of cancers, have gained FDA approvals, contributing to the industry's momentum. The approval of cutting-edge drugs such as CAR-T cell therapies for certain cancers exemplifies the market's growing focus on precision medicine, offering hope for previously untreatable conditions. A notable advancement is the continued progression in immuno-oncology treatments, which are redefining cancer care.

In the U.S. market for pharmaceuticals, the transformative clinical outcomes of GLP-1 receptor agonists and GLP-1/GIP dual agonists, have set a new benchmark for obesity treatment. As they are emerged as transformative therapies, delivering unprecedented clinical results. These medications, such as semaglutide and tirzepatide, have demonstrated weight loss of up to 25%, significantly outperforming earlier drug classes, which achieved only about 7% weight reduction. This breakthrough has reshaped the obesity treatment paradigm for both patients and providers, offering a viable medical solution to a condition long viewed as difficult to manage. Coupled with advances in digital health tools, these therapies are part of integrated care models that combine pharmacological treatments with technology, behavioral coaching, and personalized interventions. This comprehensive approach not only addresses obesity but also improves overall patient outcomes, presenting a credible pathway to overcoming a major public health challenge in the U.S.

Pharmaceutical R&D spending in the U.S. has been a pivotal driver of market growth, with the sector continuously investing in the discovery and development of new therapies. In 2023, pharmaceutical companies in the U.S. spent over USD 80 billion on R&D, a figure that continues to rise annually. Major companies like Johnson & Johnson, Merck, and Eli Lilly have earmarked significant portions of their revenues to R&D, recognizing the importance of developing innovative drugs to meet the demands of an aging population and the increasing prevalence of chronic diseases.

This high level of investment fuels the discovery of breakthrough therapies across various segments, including oncology, immunology, and rare diseases. According to an article by oxford Academic, in 2023, U.S. pharmaceutical spending rose by 13.6% to reach USD 722.5 billion. This increase was driven by a 6.5% rise in utilization, a 4.2% boost from new drugs, and a 2.9% uptick in prices. The top-selling drug of 2023 was semaglutide, followed by adalimumab and apixaban. Furthermore, In 2023, drug spending in nonfederal hospitals decreased by 1.1%, totaling USD 37.1 billion, while expenditures in clinics increased by 15.0% to USD 135.7 billion. Clinic growth was driven by higher utilization, with a minor impact from new products and price changes. In nonfederal hospitals, lower utilization led to reduced spending, while new drugs and prices had a modest influence. Several new drugs expected in 2024, especially in specialty, endocrine, and cancer treatments, will continue to drive spending.

The growing market adoption of innovative and modern medicines is another key driver of the U.S. pharmaceutical market. As patients and healthcare providers become more aware of the effectiveness of new treatments, there is an increasing demand for cutting-edge therapies that offer better outcomes and fewer side effects. The uptake of biologics, gene therapies, and immunotherapies in oncology, autoimmune diseases, and other areas has been particularly notable. For example, the rapid adoption of monoclonal antibodies, such as those used in immuno-oncology, has transformed the treatment landscape, with market leaders like Keytruda and Opdivo showing impressive year-on-year sales growth. Recently, in September 2024, the API Innovation Center received USD 14 million in strategic funding aimed at strengthening U.S. pharmaceutical independence. The funding will support the development of critical Active Pharmaceutical Ingredients (API) manufacturing capabilities within the U.S., enhancing resilience in the supply chain and reducing reliance on foreign sources. This initiative aligns with efforts to bolster domestic production, improve national security, and ensure consistent access to essential medicines.

However, Patent expiration of key pharmaceutical drugs has emerged as a significant restraint for the growth of the U.S. pharmaceutical industry. Once patents expire, generic versions of these drugs can enter the market, often leading to a sharp decline in sales for the original branded drugs. For instance, in January 2023, the patent for AbbVie's blockbuster drug Humira (adalimumab), which generated over USD 20 billion in annual sales, expired, allowing biosimilars to compete. The shift from branded to generic drugs reduces the market share of originator companies and significantly impacts their revenue streams. The overall market dynamics are also affected by the pricing pressure brought on by these generics, forcing branded companies to reduce prices or find new market niches. This change is particularly evident in the biologics market, where patents for key products like Enbrel and Herceptin have expired, opening the door for cheaper alternatives.

U.S. Pharmaceutical Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. pharmaceutical market report based on molecule, product, type, disease, route of administration, age group, and distribution channel:

• Molecule Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Biologics & Biosimilars (Large Molecules)
  • Monoclonal Antibodies
  • Vaccines
  • Cell & Gene Therapy
  • Others
• Conventional Drugs (Small Molecules)
• Product Outlook (Revenue, USD Billion, 2018 - 2030)
• Branded
• Generic
• Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Prescription
• OTC
• Disease Outlook (Revenue, USD Billion, 2018 - 2030)
• Cardiovascular diseases
• Cancer
• Diabetes
• Infectious diseases
• Neurological disorders
• Respiratory diseases
• Autoimmune diseases
• Mental health disorders
• Gastrointestinal disorders
• Women's Health Diseases
• Genetic and Rare genetic diseases
• Dermatological conditions
• Obesity
• Renal diseases
• Liver conditions
• Hematological disorders
• Eye conditions
• Infertility conditions
• Endocrine disorders
• Allergies
• Others
• Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
• Oral
  • Tablet Capsule
  • Suspensions
  • Other
• Topical
• Parenteral
  • Intravenous
  • Intramuscular
• Inhalations
• Other
• Age Group Outlook (Revenue, USD Billion, 2018 - 2030)
• Children & Adolescents
• Adults
• Geriatric
• Distribution Channel Group Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacy
• Retail Pharmacy
• Others

Table of Contents

Chapter 1. U.S. Pharmaceutical Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Objectives
  • 1.3.1. Objective - 1
  • 1.3.2. Objective - 2
  • 1.3.3. Objective - 3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations

Chapter 2. U.S. Pharmaceutical Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Pharmaceutical Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing healthcare spending by the government
    • 3.2.1.2. Improving affordability driven by rising per capita income
    • 3.2.1.3. Increasing awareness about healthcare among the population
    • 3.2.1.4. Increasing access to innovative and modern medicines
    • 3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
    • 3.2.1.6. Rising chronic diseases and geriatric population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. COVID-19 pandemic
    • 3.2.2.2. Intensification of competition from generic and biosimilar drugs
    • 3.2.2.3. Increasing price-sensitivity of customers for non-reimbursed drugs
    • 3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
• 3.3. Porter's Five Forces Analysis
• 3.4. PESTLE Analysis

Chapter 4. U.S. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis

• 4.1. Molecule Type Outlook: Movement Analysis
• 4.2. Biologics & Biosimilars (Large Molecules)
  • 4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.1.1 Biologics & Biosimilars (Large Molecules)
    • 4.2.1.2 Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.1.2.1 Monoclonal Antibodies
      • 4.2.1.2.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.3.1 Vaccines
    • 4.2.3.2 Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.3.1.1 Cell & Gene Therapy
      • 4.2.3.3.2 Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.5.1 Others
    • 4.2.5.2 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
• 4.3. Conventional Drugs (Small Molecules)
  • 4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Pharmaceutical Market: Product Estimates & Trend Analysis

• 5.1. U.S. Pharmaceutical Market: Product Movement Analysis
• 5.2. Branded
  • 5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.3. Generic
  • 5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Pharmaceutical Market: Type Estimates & Trend Analysis

• 6.1. U.S. Pharmaceutical Market: Type Movement Analysis
• 6.2. Prescription
  • 6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.3. OTC
  • 6.3.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. U.S. Pharmaceutical Market: Disease Outlook Estimates & Trend Analysis

• 7.1. U.S. Pharmaceutical Market: Disease Outlook Movement Analysis
• 7.2. Cardiovascular diseases
  • 7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.3. Cancer
  • 7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.4. Diabetes
  • 7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Infectious diseases
  • 7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.6. Neurological disorders
  • 7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.7. Respiratory diseases
  • 7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.8. Autoimmune diseases
  • 7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.9. Mental health disorders
  • 7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.10. Gastrointestinal disorders
  • 7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.11. Women's Health Diseases
  • 7.11.1. Women's Health Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.12. Genetic and Rare genetic diseases
  • 7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.13. Dermatological conditions
  • 7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.14. Obesity
  • 7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.15. Renal diseases
  • 7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.16. Liver conditions
  • 7.16.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.17. Hematological disorders
  • 7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.18. Eye conditions
  • 7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.19. Infertility conditions
  • 7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.20. Endocrine disorders
  • 7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.21. Allergies
  • 7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.22. Others
  • 7.22.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. U.S. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

• 8.1. U.S. Pharmaceutical Market: Route of Administration Movement Analysis
• 8.2. Oral
  • 8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.3. Topical
  • 8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.4. Parenteral
  • 8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.1.1. Intravenous
    • 8.4.1.2. Intramuscular
• 8.5. Inhalations
  • 8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.6. Other
  • 8.6.1. Other Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. U.S. Pharmaceutical Market: Age Group Estimates & Trend Analysis

• 9.1. U.S. Pharmaceutical Market: Age Group Movement Analysis
• 9.2. Children & Adolescents
  • 9.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.3. Adults
  • 9.3.1. Adults Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 9.4. Geriatric
  • 9.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. U.S. Pharmaceutical Market: Distribution Channel Group Estimates & Trend Analysis

• 10.1. U.S. Pharmaceutical Market: Distribution Channel Group Movement Analysis
• 10.2. Hospital Pharmacy
  • 10.2.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 10.3. Retail Pharmacy
  • 10.3.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 10.4. Others
  • 10.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
• 11.2. Strategy Mapping
  • 11.2.1. NEW PRODUCT LAUNCH
  • 11.2.2. PARTNERSHIPS
  • 11.2.3. ACQUISITION
  • 11.2.4. COLLABORATION
  • 11.2.5. FUNDING
• 11.3. Key Company Market Share Analysis, 2024
• 11.4. Company Heat Map Analysis
• 11.5. Company Profiles
  • 11.5.1. F. HOFFMANN-LA ROCHE LTD
    • 11.5.1.1. Company Overview
    • 11.5.1.2. Financial Performance
    • 11.5.1.3. Product Benchmarking
    • 11.5.1.4. Strategic Initiatives
  • 11.5.2. NOVARTIS AG
    • 11.5.2.1. Company Overview
    • 11.5.2.2. Financial Performance
    • 11.5.2.3. Product Benchmarking
    • 11.5.2.4. Strategic Initiatives
  • 11.5.3. ABBVIE INC.
    • 11.5.3.1. Company Overview
    • 11.5.3.2. Financial Performance
    • 11.5.3.3. Product Benchmarking
    • 11.5.3.4. Strategic Initiatives
  • 11.5.4. JOHNSON & JOHNSON SERVICES, INC.
    • 11.5.4.1. Company Overview
    • 11.5.4.2. Financial Performance
    • 11.5.4.3. Product Benchmarking
    • 11.5.4.4 Strategic Initiatives
  • 11.5.5. MERCK & CO., INC.
    • 11.5.5.1. Company Overview
    • 11.5.5.2. Financial Performance
    • 11.5.5.3. Product Benchmarking
    • 11.5.5.4. Strategic Initiatives
  • 11.5.6. PFIZER INC.
    • 11.5.6.1. Company Overview
    • 11.5.6.2. Financial Performance
    • 11.5.6.3. Product Benchmarking
    • 11.5.6.4. Strategic Initiatives
  • 11.5.7. BRISTOL-MYERS SQUIBB COMPANY
    • 11.5.7.1. Company Overview
    • 11.5.7.2. Financial Performance
    • 11.5.7.3. Product Benchmarking
    • 11.5.7.4. Strategic Initiatives
  • 11.5.8. SANOFI
    • 11.5.8.1. Company Overview
    • 11.5.8.2. Financial Performance
    • 11.5.8.3. Product Benchmarking
    • 11.5.8.4. Strategic Initiatives
  • 11.5.9. GSK PLC.,
    • 11.5.9.1. Company Overview
    • 11.5.9.2. Financial Performance
    • 11.5.9.3. Product Benchmarking
    • 11.5.9.4. Strategic Initiatives
  • 11.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 11.5.10.1. Company Overview
    • 11.5.10.2. Financial Performance
    • 11.5.10.3. Product Benchmarking
    • 11.5.10.4. Strategic Initiatives